While the national life sciences sector grapples with high vacancy rates and a sharp decline in venture capital, New Jersey’s specialized real estate market is showing signs of resilience. According to the latest data from Colliers’ 2026 Life Sciences Market Outlook, the Garden State has successfully navigated the “post-pandemic saturation” that has left other major hubs like Boston and San Francisco struggling with record-high inventories.
Nationally, the sector is recalibrating after a historic construction wave. However, New Jersey—which has historically been more disciplined with new supply—recorded one of the lowest amounts of new lab space completions in 2025. This scarcity, combined with the state’s role as a global pharmaceutical stronghold, has allowed local vacancy rates to grow far more slowly than the national average, creeping up only slightly from 14.4% to 14.9%.
Despite a cooling IPO market, New Jersey continues to attract major tenants who prioritize move-in-ready facilities and the state’s high density of specialized talent.
“The calculus for many firms is shifting,” noted regional market analysts. “In 2025, we saw a flight to quality. Companies aren’t just looking for space; they are looking for ecosystems that connect R&D with manufacturing.”
Key 2025/2026 Jersey Milestones:
- Legend Biotech HQ: The cell therapy leader signed a 57,325-square-foot lease at 77 Corporate Drive in Bridgewater, establishing its new global headquarters.
- The HELIX Launch: Portal Innovations officially agreed to occupy 30,000 square feet at the highly anticipated Helix development in downtown New Brunswick, serving as a critical incubator for early-stage startups.
- Kenvue’s Summit Campus: The consumer health giant (a Johnson & Johnson spinoff) recently opened its purpose-built global headquarters in Summit, featuring 290,000 square feet of office and laboratory space designed to bridge the gap between product design and consumer feedback.
While cities like Boston and San Diego now face vacancy rates exceeding 20% due to speculative overbuilding, New Jersey’s supply remains concentrated in prime, repurposed legacy campuses.
The NEST (Northeast Science & Technology) Center in Kenilworth is currently undergoing a multimillion-dollar renovation to modernize its existing lab blocks. This focus on adaptive reuse rather than ground-up speculative builds has protected the state from the “distressed buying opportunities” currently appearing in more saturated markets.
Looking ahead, the sector expects a “measured phase of growth” driven by several emerging tailwinds:
- GLP-1 Demand: The global explosion in demand for weight-loss medications like Ozempic and Wegovy is driving a need for specialized GMP manufacturing facilities, a sector where New Jersey ranks second nationally.
- AI Integration: The increasing use of AI in drug discovery is shifting tenant needs toward higher-power, data-ready lab environments.
- Onshoring Momentum: Supply chain vulnerabilities are prompting more firms to bring manufacturing back to the U.S., benefiting Jersey’s robust logistics and production infrastructure.
